Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 4/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12695835 | 0.90 | NR1I2 (0.38) | CSNK2A1F2CSNK2A2L3MBTL1 | |
| SCHEMBL22508149 | 0.89 | F2 (0.34) | CSNK2A1F2CSNK2A2L3MBTL1 | |
| SCHEMBL22508201 | 0.84 | F2 (0.36) | CSNK2A1F2L3MBTL1 | |
| SCHEMBL22508171 | 0.80 | CSNK2A1 (0.39) | CSNK2A1F2CSNK2A2L3MBTL1KDM4E | |
| SCHEMBL22508203 | 0.78 | F2 (0.33) | F2 | |
| SCHEMBL3420582 | 0.78 | — | — | |
| SCHEMBL25522772 | 0.77 | F2 (0.41) | CSNK2A1F2CSNK2A2L3MBTL1KDM4E | |
| SCHEMBL18539035 | 0.74 | CA2 (0.32) | — | |
| SCHEMBL12700722 | 0.72 | CA2 (0.31) | — | |
| SCHEMBL30179199 | 0.72 | DGAT1 (0.34) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020205564-A1 | CYTOTOXIC BIS-BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF WITH CELL-BINDING AGENTS FOR INHIBITING ABNORMAL CELL GROWTH OR FOR TREATING PROLIFERATIVE DISEASES | IMMUNOGEN, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| EP-3666289-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10570212-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-3053600-B1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2020-01-29 | — | — | EP | disclosed |
| US-20190263924-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2019-08-29 | — | — | US | disclosed |
| US-10179818-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-9840564-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170044266-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9434748-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| EP-3053600-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160108129-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2016-04-21 | — | — | US | disclosed |
| EP-2675479-B1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-9169272-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150099874-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2015-04-09 | — | — | US | disclosed |
| US-8889669-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8765740-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140088089-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES AND METHODS OF PREPARATION | IMMUNOGEN, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20130302359-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2013-11-14 | — | — | US | disclosed |
| WO-2012128868-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20120244171-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179818-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | CSNK2A1 1225/4885F2 3599/4885CSNK2A2 1384/4885 |
| US-10570212-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | CSNK2A1 1225/4885F2 3599/4885CSNK2A2 1384/4885 |
| US-20150099874-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | CSNK2A1 1225/4885F2 3599/4885CSNK2A2 1384/4885 |
| US-20140088089-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES AND METHODS OF PREPARATION | GABRA5, GABRA4, GABRP | CSNK2A1 1401/4885F2 1890/4885CSNK2A2 1651/4885 |
| US-20160108129-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | CSNK2A1 1225/4885F2 3599/4885CSNK2A2 1384/4885 |
| US-20130302359-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | CSNK2A1 1225/4885F2 3599/4885CSNK2A2 1384/4885 |
| US-20170044266-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | CSNK2A1 1225/4885F2 3599/4885CSNK2A2 1384/4885 |
| US-20120244171-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | CSNK2A1 1225/4885F2 3599/4885CSNK2A2 1384/4885 |
| US-20190263924-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | CSNK2A1 1225/4885F2 3599/4885CSNK2A2 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.